ArticleCellular and molecular life sciences : CMLS2026
FOXK1 induced upregulation of KIF20A promotes hepatocellular carcinoma progression via Wnt/β-Catenin/EMT signaling.
Article in Cellular and molecular life sciences : CMLS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- FOXK1: a multifaceted regulator in metabolic reprogramming and disease progression.Biology direct · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver cancer ranks sixth in incidence and third in mortality worldwide, with hepatocellular carcinoma (HCC) accounting for 90% of cases. Kinesin family genes (KIFs) have been implicated in HCC progression, but their specific roles remain unclear. Here, using multiple transcriptomic datasets and machine learning, we systematically screened KIF genes in HCC and identified nine key differentially expressed KIFs (KIF3A, KIF3B, KIF5B, KIF11, KIF13A, KIF13B, KIF20A, KIFC3, KLC2) as diagnostic biomarkers. A logistic regression model showed excellent diagnostic accuracy (AUC = 0.992) in the GSE121248 dataset. Six genes (KIF3A, KIF5B, KIF11, KIF13B, KIF20A, KLC2) were validated in TCGA, several correlating with prognosis. Notably, KIF20A was an independent prognostic factor, validated across cohorts. Single-cell and experimental data revealed high KIF20A expression in HCC cells, promoting proliferation and migration. Mechanistically, KIF20A drives tumor growth and metastasis via Wnt/β-catenin signaling and epithelial-mesenchymal transition (EMT) proteins such as N-cadherin, Slug, Snail, and Twist1/2. Wnt pathway activator SKL2001 and inhibitor LGK974 confirmed KIF20A's role in tumor progression. Upstream, the transcription factor FOXK1 was identified as a key positive regulator of KIF20A. FOXK1 is overexpressed in HCC, strongly correlates with KIF20A, and predicts poor prognosis. ChIP-seq and promoter assays verified FOXK1's direct binding to the KIF20A promoter, activating its transcription. In conclusion, KIF20A serves as a diagnostic and prognostic biomarker promoting HCC progression via Wnt/β-catenin signaling, regulated by FOXK1, offering new therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.